Table 5 Summary of published studies of SBRT-treated centrally located lung tumors

Timmerman [10]

70

T1-T2,N0M0 NSCLC

60-66 Gy/3 Fx

17.5

2-yr: 95 %

2-yr: 54.7 %

Milano [13]

53

Primary, Metastases

30-63 Gy/2.5-5 Fx

10

2-yr: 73 %

2-yr:

Stage I: 72 %

Stage II-III:12 %

Mets: 49 %

Song [9]

32

Stage I NSCLC

40-60 Gy/3-4 Fx

26.5

2-yr: 85.3 %

1-yr: 70.9 %

2-yr: 38.5 %

Unger [18]

20

Hilar lesions -Primary, Metastases

30-40 Gy/5 Fx

10

1-yr: 63 %

1-yr: 54 %

Haasbeek [12]

63

Stage I-II NSCLC

60 Gy/8 Fx

35

2-yr: 92.6 %

2-yr: 69 %

5-yr: 92.6 %

5-yr: 49.5 %

Rowe [16]

47

Primary, Metastases

BED₁₀: 60–151.2/3-5 Fx

11.3

2-yr: 94 %

NA

BED ≥ 100 Gy: 100 %

BED < 100 Gy: 80 %

Nuyttens [14]

56

Primary, Metastases

45-60 Gy/5-6 Fx

23

2-yr: 76 %

2-yr: 60 %

BED > 100: 85 %

3-yr: 53 %

BED ≤ 100: 60 %

Chang [11]

100

Primary, isolated recurrences

50 Gy/4 Fx

30.6

3-yr: 96.5 %

3-yr: 70.5 %

70 Gy/5 Fx

Bahig [19]

39

T1-T2N0 NSCLC

Median BED₁₀: 113 Gy (range 106–180 Gy)

22

2-yr: 89 %

2 yr: 74 %

Schanne [17]

90

Stage I/II

24 – 60 Gy/1-18 Fx

18.8

1-yr: 76 %

1-yr: 72 %

2-yr: 64 %

3-yr: 29 %

3-yr: 52 %

Current study

111

T1-T2 NSCLC, Metastases

20 – 60 Gy/1-5 Fx

17

1-yr: 89 %

2-yr:

2-yr: 72 %

T1: 79 %

T2: 32.1 %

Mets: 49.6 %